Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Weekly Wrap 29 September

Grady Wulff
September 29, 2023

Morning Bell 29 September

Sam Kanaan
September 29, 2023

Morning Bell 28 September

Grady Wulff
September 28, 2023

Morning Bell 27 September

Grady Wulff
September 27, 2023

Morning Bell 26 September

Sam Kanaan
September 26, 2023

Morning Bell 25 September

Grady Wulff
September 25, 2023

Morning Bell 22 September

Sam Kanaan
September 22, 2023

Morning Bell 21 September

Sophia Mavridis
September 21, 2023

Morning Bell 20 September

Sam Kanaan
September 20, 2023

Morning Bell 19 September

Sophia Mavridis
September 19, 2023

Morning Bell 18 September

Sam Kanaan
September 18, 2023

Weekly Wrap 15 September

Grady Wulff
September 15, 2023